New insights into HER2-low breast cancer brain metastasis: A retrospective analysis

CONCLUSIONS: Patients diagnosed with HER2-low BCBM exhibited a more favorable prognosis than those with HER2-zero BCBM, particularly within the HR-negative subgroup. The low expression of HER2 is supposed to be linked to the prolonged survival of BCBM patients.PMID:38176304 | DOI:10.1016/j.breast.2023.103669

Source: Breast - January 4, 2024 Category: Cancer & Oncology Authors: Hangcheng Xu Yan Wang Li Li Yiqun Han Yun Wu Qiang Sa Binghe Xu Jiayu Wang Source Type: research